Michal Kantecki
- Infectious Diseases top 5%
- Antifungal resistance and susceptibility 10
- Antimicrobial Resistance in Staphylococcus 9
-
- Antibiotic Use and Resistance 4
- Molecular Medicine top 10%
- Antibiotic Resistance in Bacteria 5
- Epidemiology top 10%
- Fungal Infections and Studies 9
- Pneumonia and Respiratory Infections 5
- Nail Diseases and Treatments 4
- Small Animals top 5%
-
- Antibiotics Pharmacokinetics and Efficacy 8
- Co-authors
- Haran T. SchlammClaudie CharbonneauGregory G. StoneAntonio PagliucaDavid I. MarksRosemary A. BarnesCarlos SolanoSajjad Haider
- Journals
- SHILAP Revista de lepidopterología (1 paper)Antimicrobial Agents and Chemotherapy (1 paper)Critical Care (1 paper)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Michal Kantecki
27 papers receiving 630 citations
Peers
Comparison fields: 5 of 80
- Infectious Diseases 503
- Applied Microbiology and Biotechnology 46
- Molecular Medicine 53
- Epidemiology 369
- Small Animals 64
Countries citing papers authored by Michal Kantecki
This map shows the geographic impact of Michal Kantecki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Kantecki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Kantecki more than expected).
Fields of papers citing papers by Michal Kantecki
This network shows the impact of papers produced by Michal Kantecki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Kantecki. The network helps show where Michal Kantecki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michal Kantecki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 7 | |
| 7 | Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System | 2022 | 3 |
| 8 | 2022 | 26 | |
| 9 | 2021 | 3 | |
| 10 | 2021 | 4 | |
| 11 | 2020 | 3 | |
| 12 | 2019 | 37 | |
| 13 | 2018 | 3 | |
| 14 | 2015 | 13 | |
| 15 | 2015 | 44 | |
| 16 | 2012 | 14 | |
| 17 | 2012 | 37 | |
| 18 | 2011 | 167 | |
| 19 | 1999 | 49 | |
| 20 | 1997 | 16 |
About Michal Kantecki
Michal Kantecki is a scholar working on Applied Microbiology and Biotechnology, Infectious Diseases and Molecular Medicine, having authored 28 papers that have together received 645 indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (10 papers), Antimicrobial Resistance in Staphylococcus (9 papers), Fungal Infections and Studies (9 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers), Pneumonia and Respiratory Infections (5 papers), Antibiotic Resistance in Bacteria (5 papers), Nail Diseases and Treatments (4 papers) and Antibiotic Use and Resistance (4 papers). The work is most often cited by research in Infectious Diseases (503 citations), Applied Microbiology and Biotechnology (46 citations) and Molecular Medicine (53 citations). Michal Kantecki has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Haran T. Schlamm, Claudie Charbonneau, Gregory G. Stone, Antonio Pagliuca, David I. Marks, Rosemary A. Barnes, Carlos Solano, Sajjad Haider, A. Khachatryan and Ľuboš Drgoňa. Their work appears in journals such as SHILAP Revista de lepidopterología, Antimicrobial Agents and Chemotherapy and Critical Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.